Seoul, South Korea – Chong Kun Dang Health, a leading healthcare company, has announced that its premium vitamin brand, Imvita, has achieved a remarkable milestone: 20 million bottles sold of its flagship product, Imvita Immuneshot, within just 1 year and 9 months of its launch. This achievement comes alongside the company's recent win of the "2024 Korea Management Award."

Launched in 2022, Imvita has quickly become a trendsetter in the vitamin market, differentiating itself from competitors with innovative dual-formulations and a stylish design. Its flagship product, Imvita Immuneshot, is an all-in-one multivitamin that combines two types of supplements for maximum efficacy.

Using 100% European-sourced premium vitamins from DSM, a world-renowned supplier with a 120-year history, Imvita Immuneshot offers a balanced blend of 18 essential nutrients, including 10 vitamins, 7 minerals, and beta-carotene. Notably, it contains up to 4,000% of the recommended daily intake of vitamin B complex, known as the "energy vitamin," to help boost energy levels.

To further strengthen its position as a vitamin specialist, Imvita plans to leverage the energetic image of its brand model, Jay Park, in future marketing campaigns.

"Imvita Immuneshot is a convenient all-in-one multivitamin that allows busy individuals to recharge their energy anytime, anywhere," said a spokesperson for Chong Kun Dang Health. "With this award, we will continue to lead the innovation of the domestic healthcare industry."

The company's success can be attributed to its commitment to providing high-quality, scientifically-backed products that cater to the needs of modern consumers. As Imvita continues to grow, it is poised to become a leading player in the global vitamin market.